BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 11127918)

  • 1. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
    Gupta D; Shidham V; Holden J; Layfield L
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms.
    Gupta D; Shidham V; Holden J; Layfield L
    Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):215-21. PubMed ID: 11556748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis.
    Gupta D; Holden J; Layfield L
    Appl Immunohistochem Mol Morphol; 2001 Mar; 9(1):86-91. PubMed ID: 11277421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas.
    Nagura S; Katoh R; Kawaoi A; Kobayashi M; Obara T; Omata K
    Mod Pathol; 1999 Dec; 12(12):1107-11. PubMed ID: 10619262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
    Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
    Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of p53, Ki-67, E-cadherin, N-cadherin and TOP2A in triple-negative breast cancer.
    Nakagawa M; Bando Y; Nagao T; Morimoto M; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Sasa M; Tangoku A
    Anticancer Res; 2011 Jun; 31(6):2389-93. PubMed ID: 21737670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenocortical neoplasms: role of prognostic markers MIB-1, P53, and RB.
    Vargas MP; Vargas HI; Kleiner DE; Merino MJ
    Am J Surg Pathol; 1997 May; 21(5):556-62. PubMed ID: 9158680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.
    Tavangar SM; Shojaee A; Moradi Tabriz H; Haghpanah V; Larijani B; Heshmat R; Lashkari A; Azimi S
    Pathol Res Pract; 2010 May; 206(5):305-9. PubMed ID: 20189725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Distinction between benign and malignant pheochromocytomas].
    Liu TH; Chen YJ; Wu SF; Gao J; Jiang WJ; Lu ZH; Guan J; Wei SZ; Luo YF; Cao JL; Wan JW
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
    Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
    Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder carcinoma.
    Ioachim E; Charchanti A; Stavropoulos NE; Skopelitou A; Athanassiou ED; Agnantis NJ
    Histol Histopathol; 2000 Jul; 15(3):721-7. PubMed ID: 10963116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
    Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
    Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.
    Vargas MP; Vargas HI; Kleiner DE; Merino MJ
    Mod Pathol; 1997 Jan; 10(1):12-7. PubMed ID: 9021722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis.
    Heidenreich A; Sesterhenn IA; Mostofi FK; Moul JW
    Cancer; 1998 Sep; 83(5):1002-11. PubMed ID: 9731905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.
    Nijman HW; Kenemans P; Poort-Keesom RJ; Verstraeten RA; Mensdorff-Pouilly S; Verheijen RH; Melief CJ; Hilgers J; Meijer CJ
    Eur J Obstet Gynecol Reprod Biol; 1999 Apr; 83(2):201-6. PubMed ID: 10391533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study.
    Fritz P; Cabrera CM; Dippon J; Gerteis A; Simon W; Aulitzky WE; van der Kuip H
    Breast Cancer Res; 2005; 7(3):R374-84. PubMed ID: 15987433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
    Hasby EA; Saied EM
    J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.